U.S. Life Sciences Stock News

NYSE:AMRC
NYSE:AMRCConstruction

Does Ameresco’s (AMRC) Landfill Solar Push Reveal a Durable Edge in Community-Scale Clean Energy?

In February 2026, Ameresco and Luminace reported the completion of the 5.740 MW Coventry Landfill Solar project in Rhode Island, while Ameresco also partnered with Bradford Exempted Village School District in Ohio on a 304 kW rooftop solar system backed by state grant funding. These projects highlight Ameresco’s ability to turn constrained landfill sites and public school rooftops into income-generating clean energy assets for local communities. Next, we’ll examine how Ameresco’s work...
NYSE:NOMD
NYSE:NOMDFood

Nomad Foods Boosts 2025 Cash Returns As 2026 Reset Targets Value Creation

Nomad Foods (NYSE:NOMD) has set a shareholder capital return plan for 2025 that lifts dividends and share repurchases by 38% year on year. The company is also preparing broad organizational and planning changes for 2026 aimed at performance and value creation. This combination of higher cash returns and a reset year ahead marks a clear shift in how Nomad Foods is approaching capital allocation and its business setup. For investors looking at the frozen foods group today, Nomad Foods trades...
NasdaqGS:INVA
NasdaqGS:INVAPharmaceuticals

Innoviva’s NUZOLVENCE Approval And Buyback Reframe Growth And Valuation Story

Innoviva (NasdaqGS:INVA) received FDA approval for NUZOLVENCE, a first in class treatment for uncomplicated urogenital gonorrhea. The company announced a US$125 million share repurchase program alongside the approval. These updates point to meaningful shifts in Innoviva's specialty therapeutics focus and capital allocation approach. For you as an investor, NUZOLVENCE adds a new approved therapy to Innoviva's portfolio, aligning with its push in specialty therapeutics. Gonorrhea treatment is...
NYSE:GAM
NYSE:GAMCapital Markets

How General American Investors’ 2025 Earnings Gap Between Revenue and Profit Could Reshape GAM’s Narrative

General American Investors Company, Inc. has reported its full-year 2025 results, posting revenue of US$24.31 million and net income of US$339.84 million for the year ended December 31, 2025. The contrast between relatively modest revenue and very large net income highlights how investment gains can significantly shape this closed-end fund’s financial profile. With this unusually wide gap between revenue and net income, we’ll explore what the latest earnings mean for General American...
NasdaqGS:FOXA
NasdaqGS:FOXAMedia

Fox Buys Supercast As It Chases Creator Subscriptions And New Revenue

Fox Corporation, ticker NasdaqGS:FOXA, has acquired podcast monetization platform Supercast. The deal brings Fox further into the podcast creator economy by adding subscription and membership tools for audio creators. Supercast is expected to continue operating independently while plugging into Fox's broader digital media ecosystem. For investors tracking NasdaqGS:FOXA, this move comes at a time when the share price stands at $54.12 and the stock has shown mixed performance across...
NYSE:HD
NYSE:HDSpecialty Retail

Home Depot (HD) Margin Compression Challenges Longstanding High Quality Retail Narrative

Setting the stage: Home Depot’s latest results Home Depot (HD) has closed out FY 2026 with fourth quarter revenue of US$38.2b, Basic EPS of US$2.59 and net income of US$2,571m, with same store sales growth of 0.4% framing a steady finish to the year. Over the past few quarters, revenue has ranged from US$38.2b to US$45.3b while Basic EPS has moved between US$2.59 and US$4.59, giving investors a clear view of how the top and bottom line are tracking through different trading periods before...
NasdaqGS:JBHT
NasdaqGS:JBHTTransportation

J.B. Hunt Shelf Registration Adds New Capital Flexibility For Growth Plans

J.B. Hunt Transport Services filed an omnibus shelf registration that covers a range of securities, including common stock, preferred shares, debt, warrants, and rights. The filing gives NasdaqGS:JBHT the ability to raise capital more quickly if it chooses to in the future. For investors watching NasdaqGS:JBHT at a current share price of $219.25, the shelf registration adds a new financing tool to the picture. The stock has returned 11.4% year to date and 38.3% over the past year, with...
NasdaqGS:SBAC
NasdaqGS:SBACSpecialized REITs

What SBA Communications (SBAC)'s International Tower Focus and Earnings Shift Means For Shareholders

SBA Communications recently prepared to report earnings that analysts expect to show lower earnings per share than last year but higher revenues, with particular strength anticipated in international site leasing and development, while its CEO Brendan Cavanagh also spoke at Deutsche Bank’s 34th Annual Media, Internet and Telecom Conference in Palm Beach. This combination of shifting earnings expectations and emphasis on international growth priorities offers insight into how SBA is...
NasdaqGS:XMTR
NasdaqGS:XMTRTrade Distributors

Is Xometry (XMTR) Pricing Still Justified After Recent Share Price Declines?

If you are wondering whether Xometry's share price still makes sense after recent swings, you are not alone. This article is going to focus squarely on what you are really paying for in the business. The stock last closed at US$41.82, with a 7 day return of 27.4% decline, a 30 day return of 34.7% decline, a year to date return of 33.4% decline, a 1 year return of 54.8%, and a 3 year return of 127.3%. Recent coverage has highlighted Xometry's position as an online marketplace for...
NYSE:BCC
NYSE:BCCTrade Distributors

Boise Cascade Weighs Growth In Distribution Against Lacey Act Uncertainty

Boise Cascade (NYSE:BCC) acquired Holden Humphrey, expanding its distribution presence in the US Northeast. The company opened a new Greenfield Distribution Center in Texas, adding capacity and reach for its Building Materials Distribution segment. Boise Cascade recorded a $6 million legal accrual related to a Lacey Act investigation tied to its distribution business. Boise Cascade is a wood products and building materials distributor that serves dealers, homebuilders, and industrial...
NasdaqGM:VNDA
NasdaqGM:VNDABiotechs

A Look At Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of Bysanti For Bipolar I Disorder And Schizophrenia

Vanda Pharmaceuticals (VNDA) is back on investors’ radar after the U.S. Food and Drug Administration approved BYSANTI tablets for bipolar I disorder and schizophrenia, while an earlier imsidolimab filing for generalized pustular psoriasis also progresses through review. See our latest analysis for Vanda Pharmaceuticals. The recent FDA approvals and filings have coincided with sharp share price moves, with a 37.31% 7 day share price return and 56.23% 90 day share price return, while the 1 year...
NasdaqGM:PVLA
NasdaqGM:PVLABiotechs

Assessing Palvella Therapeutics (PVLA) Valuation After Its Recent Share Price Surge

Why Palvella Therapeutics Has Caught Investor Attention Recent trading in Palvella Therapeutics (PVLA) has drawn attention after a sharp share price move, with the stock closing at US$128.60 and posting very large 1 year total returns. That type of performance, together with reported annual revenue growth of 63.12% and net income growth of 54.52% on a net loss of US$32.37 million, is prompting investors to reassess how they view this clinical stage biopharmaceutical name. See our latest...
NYSE:AXS
NYSE:AXSInsurance

Board Change At AXIS Capital Raises Questions On Valuation And Governance

AXIS Capital Holdings (NYSE:AXS) announced the retirement of board member Thomas Ramey. His retirement represents a change in the company’s board-level governance structure. For you as an investor, board changes at an insurer like AXIS Capital Holdings matter because they sit close to decisions on risk appetite, capital allocation and long term priorities. The company operates in specialty insurance and reinsurance, areas that can be influenced by evolving regulation and changing views on...
NYSE:ALSN
NYSE:ALSNMachinery

Allison Transmission Holdings (ALSN) Margin Compression Challenges Long‑Term Profitability Narrative

Allison Transmission Holdings (ALSN) closed out FY 2025 with Q4 revenue of US$737 million and basic EPS of US$1.19, alongside net income of US$99 million that sets the tone for how investors read the full year. The company has seen quarterly revenue move from US$824 million in Q3 2024 to US$814 million in Q2 2025, US$693 million in Q3 2025 and then US$737 million in Q4 2025. Basic EPS shifted from US$2.30 to US$2.32, US$1.63 and US$1.19 over the same stretch, giving a clear read on how top...
NYSE:MHO
NYSE:MHOConsumer Durables

Is It Too Late To Consider M/I Homes (MHO) After Its Strong Multi Year Rally?

If you are wondering whether M/I Homes is still good value after a strong multi year run, this article walks through how its current share price stacks up against several valuation measures. The stock closed at US$140.40 recently, with returns of 4.8% over 30 days, 9.8% year to date and 17.9% over 1 year. The 3 year return sits at a very large 138.7%, and the 5 year return at 180.7%. Recent coverage of M/I Homes has focused on its position within the U.S. homebuilding sector and how...
NYSE:NX
NYSE:NXBuilding

How Margin Deterioration Amid Revenue Growth At Quanex Building Products (NX) Has Changed Its Investment Story

Over the past few years, Quanex Building Products has experienced a significant drop in operating margin, earnings per share, and return on invested capital despite continuing to grow its revenue base. This combination of rising costs and weaker profitability on a per‑share and invested‑capital basis points to mounting operational pressures and fewer attractive growth opportunities within the business. Next, we’ll examine how this sustained margin deterioration challenges Quanex’s earlier...
NYSE:ITW
NYSE:ITWMachinery

Illinois Tool Works Credit Facility Refreshes Liquidity As Valuation Runs Rich

Illinois Tool Works (NYSE:ITW) has entered into a new US$3.0b five year revolving credit facility. The agreement replaces the company’s previous revolving credit facility more than a year before its scheduled expiry. The facility includes multi currency and rate options and can be increased to up to US$5b, subject to conditions. Illinois Tool Works, a diversified industrial manufacturer serving multiple end markets, now has a refreshed liquidity backstop that can support its ongoing...
NYSE:HPQ
NYSE:HPQTech

HPQ Q1 2026 Margin Compression Reinforces Bear Narratives On Profitability

HP (HPQ) has opened Q1 2026 with revenue of US$14.4b and basic EPS of US$0.59, putting fresh numbers on the table for investors tracking how the story is evolving. The company has seen quarterly revenue move from US$14.1b in Q4 2024 to US$13.5b in Q1 2025 and US$14.4b in Q1 2026, while basic EPS has shifted from US$0.94 to US$0.60 and now US$0.59, setting a clear earnings run rate for the latest quarter. With these results in hand, the focus now turns to what they signal about HP's margin...
NasdaqGS:AXON
NasdaqGS:AXONAerospace & Defense

US Stock Market Today: S&P 500 Futures Dip As Rate Cut Expectations Cool

The Morning Bull - US Market Morning Update Thursday, Feb, 26 2026 US stock futures are mixed this morning, with S&P 500 contracts slightly softer while Nasdaq 100 and Dow futures hold near flat, as investors weigh stronger global growth signals against interest rate worries. Taiwan just reported a record current account surplus of about US$69.9b, powered by a US$63.6b goods trade surplus tied to AI and electronics exports, which underlines how demand for chips and hardware is feeding into...
NasdaqGM:SHLS
NasdaqGM:SHLSElectrical

Is Shoals Technologies Group (SHLS) Pricing Look Reasonable After The Recent Share Price Slump

If you are looking at Shoals Technologies Group and wondering whether the current share price reflects its true value, this article will walk you through what the numbers are saying in plain terms. The stock last closed at US$6.85, with returns of a 36.2% decline over 7 days, a 26.1% decline over 30 days, a 24.6% decline year to date, a 76.8% gain over 1 year, a 72.8% decline over 3 years and a 79.8% decline over 5 years, which gives a mixed picture of recent and longer term...
NasdaqGM:IOVA
NasdaqGM:IOVABiotechs

Iovance Lifileucel Data Points To Broader Solid Tumor Opportunity

Iovance Biotherapeutics (NasdaqGM:IOVA) reported encouraging clinical trial data for lifileucel in patients with advanced sarcoma. The company plans to initiate a registrational trial and pursue accelerated FDA approval for lifileucel in this sarcoma setting. Iovance also received FDA Fast Track designation for lifileucel in non-small cell lung cancer. Iovance Biotherapeutics focuses on developing tumor infiltrating lymphocyte (TIL) therapies for difficult-to-treat cancers. The new sarcoma...
NYSE:CRK
NYSE:CRKOil and Gas

Dallas Salazar’s New Family Office Renews Focus On Comstock Resources

Early Comstock Resources investor Dallas C. Salazar has launched a new family office, Two Texas Presidents, focused on energy sector investments. Salazar has been involved in prior acquisition events at Comstock Resources, which brought him significant gains. The new family office keeps attention on Comstock Resources' history with high profile energy investors such as Salazar. For investors watching Comstock Resources (NYSE:CRK), the launch of Two Texas Presidents adds context around the...
NYSE:TFC
NYSE:TFCBanks

Truist Bitcoin ETFs And Open Banking Move Tie Into Undervalued Shares

Truist Financial (NYSE:TFC) is offering clients access to SEC registered spot Bitcoin ETFs through Truist Investment Services Inc. The bank has also launched open banking connectivity in partnership with Mastercard, giving clients new ways to link and manage financial data. These moves expand Truist Wealth's product shelf and introduce new digital tools for clients who want broader choice and more control. For a large US regional bank focused on retail, wealth, and commercial banking, this...
NasdaqGM:MNKD
NasdaqGM:MNKDBiotechs

United Therapeutics Rival Inhaler Tests MannKind Valuation And Royalty Outlook

United Therapeutics has introduced a new soft mist inhaler that is positioned as a direct competitor to MannKind's Tyvaso DPI. The new device is described as offering reduced side effects, including less coughing, compared with dry powder inhalers. This development raises questions about the durability of MannKind's royalty stream from Tyvaso DPI and could influence investor expectations for NasdaqGM:MNKD. MannKind, trading on NasdaqGM:MNKD, is closely tied to royalties from Tyvaso DPI, so...